The widely prescribed drug tamoxifen already plays a major role in reducing the risk of death from breast cancer. But a new study suggests that women should be taking the drug for twice as long as is now customary, a finding that could upend the standard that has been in place for about 15 years. Paul E. Goss, HMS professor of medicine at Massachusetts General Hospital; Eric P. Winer, HMS professor of medicine; and Judy E. Garber, HMS professor of medicine, both of Dana-Farber Cancer Institute, are quoted.
